Longevity technology faces a validation and access test

The longevity technology boom is increasingly focused on biological-age measurement, telomere and epigenetic panels, prevention workflows, personal-health datasets, and emerging pharmaceutical and regulatory frameworks for aging trials. Biomarkers and candidate gerotherapeutics remain investigational; privacy, equity, reproducibility, clinical integration, and proof of meaningful outcomes remain unresolved.